On May 19, 2026 Defence Therapeutics Inc. ("Defence" or the "Company"), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular drug-delivery company, reported the expansion of internal capabilities to execute critical stages of its ACCUM‑enabled Antibody Drug Conjugates ("ADC") development pipeline. The Company has strengthened its purification, analytical characterization, conjugation development, and quality control ("QC") capabilities, while enhancing cellular testing and potency evaluation workflows within a more structured stage-gated framework to better support the advancement of its ADC partnership programs.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"By strengthening our internal QC, analytical, and conjugation capabilities, Defence is positioning itself to become a leading authority in the development and controlled manufacture of ACCUM-enabled ADCs," said Mark Lambermon, PhD, Head of Quality & Operations at Defence Therapeutics. "Our focus is to establish robust, reproducible, and quality-driven processes that support the consistent generation of high-quality ACCUM-ADC candidates for our partnership programs."
To support the development of high-quality ACCUM-enabled ADC candidates, the Company has acquired an FPLC system to improve purification workflows and the consistency of conjugated materials, while also advancing the evaluation of multiple conjugation methods, including site specific strategies. These efforts are guided by a structured framework designed to identify the most suitable conjugation approach for each partner ADC based on format, chemistry compatibility, Drug-to-Antibody Ratio ("DAR") profile, and developability characteristics such as stability and aggregation.
In parallel, Defence Therapeutics is enhancing its analytical characterization and QC infrastructure through standardized analytical checkpoints, documentation practices, and reproducibility-focused processes designed to support reliable decision-making and partner-ready execution.
The Company has also expanded its cellular testing capabilities with the addition of an Incucyte live-cell imaging platform designed to generate kinetic potency and mechanism-relevant cellular data designed to better assess the internalization, intracellular delivery, and cellular potency of ACCUM-enabled ADC candidates. These capabilities are being integrated within a more structured stage-gated governance framework with clearly defined success criteria to support efficient lead candidate selection and downstream validation activities.
"As we continue to grow our ADC partnership activities, it is important that our internal capabilities evolve alongside the needs of our partners," said Amie Phinney, PhD, Defence Therapeutics’ Strategy & Business Advisor. "These expanded capabilities strengthen our ability to tailor ACCUM integration and support partner programs with greater confidence and precision."
"By bringing key development and analytical capabilities in-house, we are strengthening our ability to rapidly evaluate and advance ACCUM-enabled ADC candidates," said Sébastien Plouffe, Chief Executive Officer of Defence Therapeutics. "These expanded capabilities position us to accelerate our ADC partnership programs and support the development of more effective ADC therapies for patients."
(Press release, Defence Therapeutics, MAY 19, 2026, View Source;utm_medium=rss&utm_campaign=defence-therapeutics-enhances-in-house-adc-development-platform-with-expanded-analytical-and-cellular-testing-capabilities [SID1234665857])